These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 21085773)

  • 1. Severe HDL-c reduction during rosiglitazone therapy in an obese woman with type 2 diabetes.
    Almeida RL; Fedrizzi P; Fedrizzi D; Almeida TS
    Arq Bras Endocrinol Metabol; 2010 Oct; 54(7):663-7. PubMed ID: 21085773
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High incidence of reduced plasma HDL cholesterol in diabetic patients treated with rosiglitazone and fibrate.
    Keidar S; Guttmann H; Stam T; Fishman I; Shapira C
    Pharmacoepidemiol Drug Saf; 2007 Nov; 16(11):1192-4. PubMed ID: 17636555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Severe hypo-alpha-lipoproteinemia during treatment with rosiglitazone.
    Sarker A; Semple RK; Dinneen SF; O'Rahilly S; Martin SC
    Diabetes Care; 2004 Nov; 27(11):2577-80. PubMed ID: 15504988
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Paradoxically decreased HDL-cholesterol levels associated with rosiglitazone therapy.
    Gutschi LM; Malcolm JC; Favreau CM; Ooi TC
    Ann Pharmacother; 2006 Sep; 40(9):1672-6. PubMed ID: 16912247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paradoxical HDL-C reduction during rosiglitazone and fibrate treatment.
    Shetty C; Balasubramani M; Capps N; Milles J; Ramachandran S
    Diabet Med; 2007 Jan; 24(1):94-7. PubMed ID: 17227331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [HDL cholesterol reduction during rosiglitazone and fenofibrate treatment in a type 2 diabetes mellitus patient with dyslipidemia].
    Im M; Kim M; Lee JK; Chang YH; Lee DY; Hong SI; Lee YY; Hong YJ
    Korean J Lab Med; 2010 Feb; 30(1):17-9. PubMed ID: 20197717
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paradoxical severe decrease in high-density lipoprotein cholesterol due to rosiglitazone-fenofibrate interaction.
    Schwing W; Hustak L; Taylor HC
    Endocr Pract; 2010; 16(3):382-8. PubMed ID: 20061291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted Proteomics Identifies Paraoxonase/Arylesterase 1 (PON1) and Apolipoprotein Cs as Potential Risk Factors for Hypoalphalipoproteinemia in Diabetic Subjects Treated with Fenofibrate and Rosiglitazone.
    Ronsein GE; Reyes-Soffer G; He Y; Oda M; Ginsberg H; Heinecke JW
    Mol Cell Proteomics; 2016 Mar; 15(3):1083-93. PubMed ID: 26667175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thiazolidinediones and lowered HDL cholesterol.
    Savage RL; Kiuru A
    Diabetes Care; 2005 Sep; 28(9):2329-30. PubMed ID: 16123514
    [No Abstract]   [Full Text] [Related]  

  • 10. Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in Type 2 diabetic patients.
    Wolffenbuttel BH; Gomis R; Squatrito S; Jones NP; Patwardhan RN
    Diabet Med; 2000 Jan; 17(1):40-7. PubMed ID: 10691158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Severe decrease in serum HDL-cholesterol during combination therapy of bezafibrate and pioglitazone.
    Senba H; Kawano M; Kawakami M
    J Atheroscler Thromb; 2006 Oct; 13(5):263-4. PubMed ID: 17146155
    [No Abstract]   [Full Text] [Related]  

  • 12. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia.
    Goldberg RB; Kendall DM; Deeg MA; Buse JB; Zagar AJ; Pinaire JA; Tan MH; Khan MA; Perez AT; Jacober SJ;
    Diabetes Care; 2005 Jul; 28(7):1547-54. PubMed ID: 15983299
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial.
    Rosenstock J; Baron MA; Dejager S; Mills D; Schweizer A
    Diabetes Care; 2007 Feb; 30(2):217-23. PubMed ID: 17259484
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Diabetic edematous maculopathy associated with rosiglitazone treatment: report of a case].
    Nyssen V; Hautenauven F; Lekeu Hinostroza JP; Guagnini AP
    Bull Soc Belge Ophtalmol; 2009; (313):39-44. PubMed ID: 20108571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fenofibrate and rosiglitazone improve quality of lipoproteins in patients with type 2 diabetes mellitus.
    Vrablík M; Dobiásová M; Stulc T; Kasalová Z; Dolezalová R; Prázný M; Fait T; Ceska R
    Neuro Endocrinol Lett; 2008 Feb; 29(1):146-50. PubMed ID: 18283261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The safety and efficacy of rosiglitazone maleate in the treatment of patients with type 2 diabetes mellitus in China].
    Zhu XX;
    Zhonghua Nei Ke Za Zhi; 2003 Sep; 42(9):636-9. PubMed ID: 14514393
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination therapy with fenofibrate and rosiglitazone paradoxically lowers serum HDL cholesterol.
    Normén L; Frohlich J; Montaner J; Harris M; Elliott T; Bondy G
    Diabetes Care; 2004 Sep; 27(9):2241-2. PubMed ID: 15333491
    [No Abstract]   [Full Text] [Related]  

  • 18. Rosiglitazone-induced anasarca without heart failure: capillary leakage?
    Dagdelen S; Kurt M; Aydin K; Bayraktar M
    Hormones (Athens); 2008; 7(2):180-3. PubMed ID: 18477557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Postmarketing pharmacovigilance of adverse drug reactions: the case of rosiglitazone in Mexico.
    Reyes-Morales H; Mino-León D; Doubova SV; Flores-Hernández S
    Int J Clin Pharmacol Ther; 2012 Jan; 50(1):1-9. PubMed ID: 22192639
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A case of rosiglitazone exposure in the second trimester of pregnancy.
    Kalyoncu NI; Yaris F; Ulku C; Kadioglu M; Kesim M; Unsal M; Dikici M; Yaris E
    Reprod Toxicol; 2005; 19(4):563-4. PubMed ID: 15749272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.